Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a <i>post hoc</i> analysis of safety and effectiveness in older (≥65 years) and younger (<65 years) patients
Older patients had higher IRs of herpes zoster and serious infection than younger patients, although tofacitinib effectiveness was similar between age groups. Discontinuation due to AEs was more common in older patients. Despite the smaller sample size of older versus younger patients, a focused evaluation of older patients is of benefit.
Authors
- Tadakazu Hisamatsu (ORCID: https://orcid.org/0000-0002-1178-3536)
- Toshimitsu Fujii (ORCID: https://orcid.org/0000-0003-3048-7270)
- Minoru Matsuura (ORCID: https://orcid.org/0000-0001-9590-2370)
- Katsuyoshi Matsuoka (ORCID: https://orcid.org/0000-0002-2950-7660)
- Takayuki Yamamoto (ORCID: https://orcid.org/0000-0001-7551-5568)
- Shoko Arai (ORCID: https://orcid.org/0000-0003-4609-1609)
- Hirotoshi Yuasa (ORCID: https://orcid.org/0009-0007-2067-7392)
- Yuki Kobayashi (ORCID: https://orcid.org/0009-0007-5048-4479)
- Yutaka Endo (ORCID: https://orcid.org/0000-0003-2006-7707)
- Keiko Sato (ORCID: https://orcid.org/0009-0009-1270-6725)
- Yasushi Mizuno (ORCID: https://orcid.org/0009-0002-7852-9046)
Institutions
- Toho University (JP)
- Kyorin University (JP)
- Yokkaichi Social Insurance Hospital (JP)
- Toho University Medical Center Sakura Hospital (JP)
- Pfizer (Japan) (JP)
Publication Details
- Journal
- Intestinal Research
- Published
- 2025-11-10
- DOI
- https://doi.org/10.5217/ir.2025.00058
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00